ALNY stock news

What Makes Alnylam (ALNY) a New Buy Stock

01:00pm, Friday, 13'th Sep 2019
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Read more
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
The Medicines Company (NASDAQ: MDCO ) stock has staged a nice recovery in the first half of 2019 after a steep 60% pullback in the second half of 2018 that dragged it to a 52-week low of $16.69 on Dec. 21. From the low, the stock rallied to an intraday peak of $38.96 on July 11, 2019, a 133% gain, only to retreat along with the broader market. Will the stock weather a market-wide downturn and resume its uptrend? Medicines Co. is a biopharma with a single-point focus of tackling cardiovascular diseases. Does this make the shares a risky bet? Chasing A Promising Opportunity About 17.3 million deaths occur globally due to cardiovascular diseases, with 854,000 of these in the U.S., according to the company, which cited WHO estimates. About 50% of atherosclerotic cardiovascular disease can be prevented by low density lipoprotein-cholesterol, or LDL-C, management. The challenges in treating cardiovascular diseases include a majority of people not achieving LDL-C goals and poor adherence to current therapy. Read more
Alnylam (ALNY) delivered earnings and revenue surprises of -1.10% and -5.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
MISSISSAUGA, ON , July 23, 2019 /CNW/ - Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the Health Canada approval and immediate availability of ONPATTRO® (patisiran) for the treatment of polyneuropathy in adult patients with hereditary Read more
Alnylam (ALNY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read more
Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1. Read more
Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria. Read more
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change Read more
Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations. Read more
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
The highly volatile biotech stocks present a high-risk-high-reward proposition. Judicious stock picking is essential to ride the superlative rally in some of these stocks in the wake of make-or-break binary events. Here's a brief on a few small-cap biotech stocks Citigroup analyst Yigal Nochomovitz recommends as investment worthy and the rationale behind the thinking. The analyst assumed coverage of these stocks on May 24. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ): Buy rating, $30 price target (154 percent upside potential) Dicerna's lead candidate DCR-PHXC is in a pivotal Phase 2 study for primary hyperoxaluria, or PH, Types 1 and 2 – a severe, genetic liver disorder that results in the overproduction of oxalate, Nochomovitz said. Although Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) has a competing product in a Phase 3 trial, the approach of its treatment candidate makes it effective only for PH Type 1, while Dicerna's is amenable to treat all three subtypes of PH, he added. Dicerna's DCR-HBV being evaluated for hepatitis B virus infection represents a large upside opportunity, … Read more

Proudly made at